Attached files
file | filename |
---|---|
EX-16.1 - EX-16.1 - Bausch Health Companies Inc. | a57974exv16w1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of the earliest event reported): November 26, 2010 (November 19, 2010)
Valeant Pharmaceuticals International, Inc.
(Exact name of registrant as specified in its charter)
Canada | 001-14956 | 98-0448205 | ||
(State or other jurisdiction of | (Commission File Number) | (IRS Employer | ||
incorporation) | Identification No.) |
7150 Mississauga Road | ||
Mississauga, Ontario | ||
Canada | L5N 8M5 | |
(Address of principal executive offices ) | (Zip Code) |
(905) 286-3000
(Registrants telephone number, including area code)
(Registrants telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 4.01. Changes in Registrants Certifying Accountant.
(a) As previously disclosed, on September 28, 2010, Valeant Pharmaceuticals International,
Inc., formerly known as Biovail Corporation (the Company), completed its merger with Valeant
Pharmaceuticals International, a Delaware corporation (VPI) (the Merger).
Prior to and after the Merger, Ernst & Young LLP (E&Y) served as the Companys independent
registered public accountant engaged as the principal accountant to audit the Companys
consolidated financial statements. Prior to the Merger, PricewaterhouseCoopers LLP (PwC) served
as VPIs independent registered public accountant engaged as the principal accountant to audit
VPIs consolidated financial statements. On November 19, 2010, the Company notified E&Y and PwC
that the Companys Audit Committee (the Audit Committee) determined to recommend to the Companys
Board of Directors (the Board) that, at the Companys annual general meeting of shareholders in
2011, the Board recommend that shareholders appoint PwC as the Companys independent registered
public accountant for the fiscal year ending December 31, 2011. The Company expects that E&Y will
continue to serve as the Companys independent registered public accountant engaged to audit the
Companys consolidated financial statements as of and for the period ending December 31, 2010. The
Company understands that E&Y intends to resign after completing such audit.
The audit report of E&Y on the consolidated financial statements of the Company as of and for
each of the two fiscal years ended December 31, 2009 and 2008 did not contain any adverse opinion
or disclaimer of opinion, nor was it qualified or modified as to uncertainty, audit scope, or
accounting principles.
During the Companys fiscal years ended December 31, 2009 and 2008, and in the Companys
subsequent interim period from January 1, 2010 through November 19, 2010, the date E&Y was notified
of the Audit Committees decision to recommend that PwC be appointed as the Companys independent
registered public accountant at the next annual general meeting of shareholders, (i) there were no
disagreements with E&Y on any matter of accounting principles or practices, financial statement
disclosure, or auditing scope or procedure, which disagreements, if not resolved to E&Ys
satisfaction, would have caused E&Y to make reference to the subject matter of the disagreement in
connection with its report, and (ii) there were no reportable events of the type described in
Item 304(a)(1)(v) of Regulation S-K.
The Company provided E&Y with a copy of this report and requested that E&Y provide a letter
addressed to the U.S. Securities and Exchange Commission stating whether it agrees with the
foregoing statements. A copy of this letter from E&Y, dated November 26, 2010, is attached hereto
as Exhibit 16.1.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. | Description of Exhibit | |
16.1
|
Letter, dated November 26, 2010, from Ernst & Young LLP. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
VALEANT PHARMACEUTICALS INTERNATIONAL, INC. |
||||
Date: November 26, 2010 | By: | /s/ Margaret Mulligan | ||
Margaret Mulligan | ||||
Executive Vice President, Chief Financial Officer | ||||
3